Jubilant Life Sciences shines on receiving USFDA approvals for 4 Dosage Formulations

Jubilant Life Science’s is currently trading at Rs 209.00, up by 4.00 points or 1.95% from its previous closing of Rs 205.00 on the BSE.

The scrip opened at Rs 208.00 and has touched a high and low of Rs 210.50 and Rs 205.25 respectively. So far 10,000 shares were traded on the counter.

The BSE group 'B' stock of face value Re 1 has touched a 52 week high of Rs 219.45 on 11-Sep-2012 and a 52 week low of Rs 154.00 on 06-Aug-2012.

Last one week high and low of the scrip stood at Rs 214.00 and Rs 196.00 respectively. The current market cap of the company is Rs 3,328 crore.

The promoters holding in the company stood at 49.04% while Institutions and Non-Institutions held 30.32% and 20.64% respectively.

Jubilant Life Sciences’ US subsidiary - Jubilant Cadista Pharmaceuticals Inc. has received approvals from the U.S. Food and Drug Administration (US FDA) for Escitalopram Tablets USP, 5mg, 10mg and 20mg, Olanzapine Orally Disintegrating Tablet 5mg, 10mg, 15 mg and 20mg, Losartan Potassium Tablets USP, 25 mg, 50mg and 100 mg and Losartan Potassium and Hydrochlorothiazide Tablets USP, 50 mg/12.5 mg, 100 mg/12.5 mg and 100 mg/25 mg.

Escitalopram is used for acute treatment of generalized anxiety disorder and acute and maintenance treatment of major depressive disorders with its branded version LEXAPRO enjoying a market size of about $ 2.7 Billion.

Olanzapine ODT is a bioequivalent generic version of ZYPREXA ZYDIS Orally Disintegrating Tablets indicated for the treatment of schizophrenia and for the short term treatment of acute manic or mixed episodes associated with Bipolar I disorder.

Losartan Potassium is a potent, highly specific angiotensin receptor blocker (ARB).It is desirable for an effective treatment of hypertension and also lowers the chance of stroke in patients with high blood pressure and heart problem called left ventricular hypertrophy.

Losartan Potassium and Hydrochlorothiazide Tablets is a combination of ARB and a diuretic.  Annual sales for the branded drug HYZAAR is approximately $ 670 Million. Jubilant has already launched generic versions of both in Europe and the two filings are awaiting approval in few other markets.

Escitalopram and Olanzapine ODT would be manufactured in Jubilant’s dosage formulations facility at Roorkee, India. Losartan Potassium and its variant would be manufactured at the facility in Maryland, USA.